Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy

Pulmonary Arterial Hypertension or PAH is a progressive condition for which there is no cure. Even with substantial pharmacologic advances in the modern treatment era, survival still remains unacceptably poor, as reported in large PAH registries. Preclinical studies suggest that the administration of allogeneic CDCs have the potential to reduce …

  • 100 views
  • 25 Mar, 2021
  • 1 location
A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis (ATLAS)

ATLAS study is a clinical trial to evaluate the potential role of subcutaneous adrenocorticotropic hormone (ACTH) gel in the management of non-infectious scleritis. Specifically, the ATLAS Study aims to evaluate the safety, tolerability and effect of 2 different dose regimens of ACTH gel administered by subcutaneous (SC) injection in patients …

  • 68 views
  • 28 Jul, 2022
  • 3 locations
Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

This is a Phase 2/3, double-blind, randomized, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in adult participants with dermatomyositis (DM).

azathioprine
methotrexate
rituximab
dermatomyositis
corticosteroids
  • 2 views
  • 11 Jul, 2022
  • 30 locations
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) (RECLAIIM)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder …

a 10
rash
myopathy
prednisolone
dermatomyositis
  • 38 views
  • 13 Jul, 2022
  • 74 locations
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring immunosuppressive medications. All study participants will have negative serologic or sub-optimal responses (defined as a Roche Elecsys® Anti-SARS-CoV-2 S (RBD) result ≤ 200 U/mL) …

ocrelizumab
hydroxychloroquine
treatment regimen
mycophenolate
methotrexate
  • 79 views
  • 24 Jul, 2022
  • 20 locations
Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM)

This study will investigate Umbilical Cord Lining Stem Cells (ULSC) as an investigational medicinal product and its use in patients with polymyositis (PM) or dermatomyositis (DM) to see if a

dermatomyositis
polymyositis
  • 4 views
  • 06 May, 2022
  • 1 location
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

dermatomyositis
  • 0 views
  • 10 Aug, 2022
  • 21 locations
Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled Trial (BIRD) (BIRD)

Dermatomyositis (DM) is a rare and disabling condition with an important impairment of quality of life and possible life-threatening complications. Treatment is based on high doses of corticosteroids but this exposes patients to adverse events (cardiovascular mortality, glucocorticoids-induced muscle and skin damages). Corticosteroids taper is associated with disease relapses. Although …

  • 0 views
  • 14 Sep, 2022
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults With Dermatomyositis (VALOR)

This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement …

dermatomyositis
corticosteroids
  • 0 views
  • 20 Sep, 2022
  • 4 locations
Exercise Capacity of Patients With Dermatomyosis

Dermatomyositis (DM) patients experience muscle weakness and low aerobic capacities, which are associated with poor health status and increased mortality. The origin of this muscle impairment remains unknown. The investigators hypothesize that mitochondria functioning is impaired in DM muscle and links with exercise capacities.

muscle biopsy
polymyositis
myopathy
dermatomyositis
weakness
  • 0 views
  • 19 Sep, 2021
  • 1 location